News

N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical firm committed to developing product candidates to address cystic fibrosis (CF), recently announced that the company has changed its name to Nivalis Therapeutics, Inc. Nivalis Therapeutics’ lead product candidate is N91115, a new inhibitor of S-nitrosoglutathione reductase (GSNOR) for the treatment of CF. The company’s new name, Nivalis…

A study led by researchers at West Virginia University presented a case report of a child who was diagnosed with cystic fibrosis (CF) based on an intussusception manifestation. The study was recently published in the Journal of Pediatric Surgery Case Reports and is entitled…

An article published in the Journal of Clinical Investigation provides evidence that challenges the previously held assumptions as to where the abnormal accumulation of sticky mucus, a key feature in cystic fibrosis (CF), originates. The study entitled “Defective goblet cell exocytosis contributes to murine cystic…

Although I am a student in a biomedical science program I have only begun in the past two years to educate myself in issues relating to Cystic Fibrosis. When I was growing up I tried to hide from any literature relating to CF in hopes that the disease would feel…

Developer of air and water filters, FiltersFast.com, is once again joining the Cystic Fibrosis Foundation (CFF) to support the fight to find a cure for cystic fibrosis (CF) by participating in the “Xtreme Hike for a Cure.” The event will be hosted…

Researchers at the University of Colorado School of Medicine at the Anschutz Medical Campus discovered a potential cause of liver disease in young people with cystic fibrosis. The study titled “Intestinal Lesions Are Associated with Altered Intestinal Microbiome and Are More Frequent in…

Garlic may help improve the symptoms of cystic fibrosis (CF) due to the presence of a chemical called allicin, which has been shown to kill opportunistic bacteria that are likely to cause lung infections in the thick, built up mucus of CF patients. The discovery that allicin may…

Drug discovery company Enterprise Therapeutics Ltd. has successfully raised $2.4 million through a Series-A financing round. The company, based at the University of Sussex in the United Kingdom, is focused on creating novel therapies for respiratory diseases, such as cystic fibrosis (CF). A portion the funding will be invested in the…

PARI Respiratory Equipment, Inc. recently announced the enrollment of the first cystic fibrosis (CF) patient in its compressor access program called PARI PROVIDE, designed to support the launch of the Kitabis Pak. The product includes a combination of a drug and the device, which has already…

A phase 2 trial from Savara Pharmaceuticals investigating its lead product AeroVanc to treat methicillin-resistant Staphylococcus aureus (MRSA) infections in cystic fibrosis patients met a key primary endpoint. Patients treated with AeroVanc experienced a significant reduction in MRSA density in their…